The University of California San Francisco Helen Diller Family Comprehensive Cancer Center is an NCI-designed matrix center conducting a wide range of inter-disciplinary research in the areas of laboratory, clinical and population sciences integrating the activities of 179 members working at multiple campuses and hospital locations. Its goals are to: (1) support cancer research of the highest possible quality, in the areas of laboratory, clinical and population sciences;(2) develop patient outreach and education programs to increase the value of the Center to the local community;(3) promote and develop first-class care for cancer patients in our affiliated hospitals;and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care. These goals are accomplished through the following 10 Programs and Shared Resources: Programs: Breast Oncology;Neurologic Oncology;Cancer, Immunity, and the Microenvironment;Prostate Cancer;Cancer Disparities;Hematopoietic Malignancies;Pediatric Malignancies;Cancer Genetics;Tobacco Control;Developmental Therapeutics. Shared Resources: Laboratory for Cell Analysis;Genome Analysis;Tissue;Immunohistochemistry &Molecular Pathology;Translational Informatics;Mouse Pathology;Preclinical Therapeutics;Computational Biology;Biostatistics;Clinical Research Support Office.

Public Health Relevance

The Helen Diller Family Comprehensive Cancer Center's goals are to: (1) support cancer research in the areas of laboratory, clinical and population sciences;(2) develop patient outreach and education programs;(3) promote and develop first-class care for cancer patients;and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA082103-16S3
Application #
8927181
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$74,999
Indirect Cost
$27,531
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications